Dr Yu said that it is crucial for providers' voices to be heard in pathway development.
Dr Yu said that it is crucial for providers’ voices to be heard in pathway development.
“If you’re going to be successful, you need to have buy-in. If you need to have buy-in, you need to have people believe that it’s a transparent process of pathways development that they respect and feel that they had a voice in,” he explained.
He detailed how a healthcare setting can also impact pathway development, and the role that published medical literature has on the real-world setting practice. The actual experience of implementing pathways and patient behavior need to be closely monitored. There should also be feedback loops that include physicians.
Dr Tischler agreed, saying that provider buy-in is necessary. He said that for authentic buy-in, one cannot force a caregiver to act or practice in a certain way.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen